8-K: BioAffinity to Present CyPath Lung Research at CHEST 2025

BioAffinity Technologies will present research supporting its noninvasive CyPath Lung test for early lung cancer detection at the CHEST 2025 annual meeting.

Summary

• BioAffinity Technologies, Inc. will present research at CHEST 2025, the annual meeting of the American College of Chest Physicians, on October 22, 2025.
• The research, titled 'The Effect of Sputum Storage and Shipping Temperature on Flow Cytometric Outcomes of Sputum-Based Diagnostic Tests,' supports the methods used for collecting and transporting patient samples for the CyPath Lung test.
• Rossella Titone, PhD, the company's project manager for product development, will present the poster at 10:20 a.m. at poster board #4324.
• CyPath Lung is a noninvasive test utilizing proprietary advanced flow cytometry and artificial intelligence to identify malignant cell populations in patient sputum.
• Clinical study results for CyPath Lung demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting lung cancer in high-risk patients with small lung nodules (less than 20 millimeters).
• The test is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Laboratory Services, a subsidiary of bioAffinity Technologies, and physicians typically receive results in two days.

Sentiment

Score: 7

Explanation: The announcement is positive, validating the company's core product and its scientific rigor. It reinforces confidence in CyPath Lung's capabilities but does not introduce new financial metrics or major strategic shifts that would significantly alter the company's outlook.

Positives

• The presented research scientifically validates the protocols for handling clinical samples, ensuring clear, accurate, and reliable results for CyPath Lung.
• CyPath Lung has demonstrated high sensitivity (92%), specificity (87%), and accuracy (88%) in detecting early-stage lung cancer, which can significantly improve patient outcomes.
• Recent announcements of multiple case studies where lung cancer was found at potentially curative Stage 1A further illustrate the value and effectiveness of CyPath Lung.
• The company is actively engaging with the medical community by presenting at a premier pulmonary conference, increasing visibility and adoption of CyPath Lung.

Risks

• Actual results could differ materially from current expectations due to various risks and uncertainties, many of which are difficult to predict.
• The benefits to be derived from the research on collecting and transporting patient samples may not materialize as expected.
• The ability of CyPath Lung to consistently identify lung cancer in a broader population may vary.
• Other factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent SEC filings could impact results.

Future Outlook

The company anticipates that the research presented will reinforce the scientific rigor behind CyPath Lung's process, leading to clear, accurate, and reliable diagnostic answers. They expect CyPath Lung to continue to identify lung cancer, particularly at early, potentially curative stages, thereby improving patient outcomes.

Management Comments

• Maria Zannes, President and CEO, stated, 'Our research reflects the scientific rigor applied to every step of the CyPath Lung process that has been shown to result in clear, accurate and reliable answers when they matter most.'
• Gordon Downie, MD, PhD, Chief Medical Officer, commented, 'This research supports the protocols we use for handling clinical samples collected at home by patients and returned to our laboratory for processing. Physicians usually receive results in two days.'
• Dr. Downie also noted, 'Our recent announcements of multiple case studies in which lung cancer was found at potentially curative Stage 1A illustrates the value of the kind of research Dr. Titone is presenting at CHEST.'

Industry Context

This announcement highlights the ongoing trend in healthcare towards noninvasive diagnostic methods and the integration of advanced technologies like flow cytometry and artificial intelligence for early disease detection. For lung cancer, early diagnosis is critical for improving survival rates, making noninvasive, accurate tests highly valuable in the pulmonary and oncology fields. The presentation at a major medical conference like CHEST 2025 positions CyPath Lung within the cutting-edge of diagnostic innovation.

Comparison to Industry Standards

• No specific comparable companies, projects, or results were mentioned in the filing to assess against global benchmarks.

Stakeholder Impact

• **Shareholders:** Positive impact through validation of a key product, potentially increasing market confidence and long-term value.
• **Patients:** Positive impact by supporting a reliable noninvasive test for early lung cancer detection, which can lead to better treatment outcomes and increased survival.
• **Physicians/Healthcare Professionals:** Provides further scientific evidence for the reliability of CyPath Lung's sample handling, potentially increasing adoption and trust in the diagnostic test.
• **Employees:** Reinforces the value of their work in product development and scientific research.

Next Steps

• Rossella Titone, PhD, will present the research poster at CHEST 2025 on October 22, 2025.
• The company will continue to market CyPath Lung as a Laboratory Developed Test (LDT) through its subsidiary, Precision Pathology Laboratory Services.
• Management looks forward to speaking with physicians and other healthcare professionals at CHEST about CyPath Lung's benefits.

Key Dates

Recommendation

The filing provides positive validation for bioAffinity Technologies' flagship product, CyPath Lung, through supporting research presented at a reputable medical conference. This reinforces the product's scientific rigor and potential for early lung cancer detection. However, the filing does not contain new financial metrics, significant strategic shifts, or catalysts that would warrant a change in investment thesis. For a seasoned investor, this news strengthens the existing 'hold' position by confirming the product's foundational science without introducing new reasons for a 'buy' or 'sell' action.

Keywords

bioAffinity Technologies, CyPath Lung, lung cancer, noninvasive diagnostic, flow cytometry, artificial intelligence, CHEST 2025, biotechnology, early detection, sputum test